Institutional investors own 91.70% of the company's stock. Vantage Investment Advisors LLC boosted its position in Boston Scientific by 228.9% in the third quarter. For the quarter, shares have been noted at 3.08%. The medical equipment provider reported $0.29 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.30 by $0.01. Quadrant Capital Group LLC boosted its position in Boston Scientific by 10.3% in the first quarter. Wade G W & Inc. now owns 22,177 shares of the medical equipment provider's stock worth $528,000 after buying an additional 200 shares in the last quarter. Elgethun Capital Management acquired a new position in Boston Scientific during the fourth quarter worth about $162,000.
In other Boston Scientific news, EVP Timothy A. Pratt sold 10,000 shares of Boston Scientific stock in a transaction on Monday, May 1st. Janus Capital Management LLC now owns 41,575,011 shares of the medical equipment provider's stock worth $899,562,000 after buying an additional 6,289,196 shares in the last quarter. JP Morgan maintained Boston Scientific Corporation (NYSE:BSX) on Friday, July 29 with "Overweight" rating. The stock traded at a volume of 7.73 million shares. The company has a market cap of $36.15 billion, a P/E ratio of 84.62 and a beta of 1.06. Boston Scientific has a 1-year low of $19.67 and a 1-year high of $26.76.
Shares of Boston Scientific Corporation (NYSE:BSX) declined -2.04% to $25.94. However the company reported $0.27 earnings per share for the same quarter during past year. The ratio dived, as 221 hedge funds increased or opened new equity positions, while 262 decreased and sold their equity positions in Boston Scientific Corp. The business had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.08 billion. During the same quarter previous year, the firm posted $0.28 earnings per share.
Receive Boston Scientific Corporation News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation with MarketBeat.com's FREE daily email newsletter.
Where's the drama? Blowouts the rule in these NBA playoffs
But the Warriors are expected to win this series especially with the lingering injury issues that have plagued Leonard so far. Due to the stiffer competition out West, the towering forward has played four more games than James in these playoffs.
Boston Scientific Co. has a 1-year low of $19.67 and a 1-year high of $26.69.
ILLEGAL ACTIVITY NOTICE: "Boston Scientific Co. (BSX) Acquired by Scout Investments Inc." was first published by Stock Observer and is owned by of Stock Observer. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & worldwide copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/05/19/toronto-dominion-bank-has-9-15-million-position-in-boston-scientific-co-bsx.html.
BSX has been the subject of several other reports. Wade G W & Inc. increased its stake in Boston Scientific by 0.9% in the third quarter. Oppenheimer Holdings Inc. set a $27.00 price target on Boston Scientific and gave the company a "hold" rating in a report on Friday, April 28th. Northland Securities reiterated a "positive" rating on shares of Boston Scientific in a report on Thursday, February 23rd.
Last time, the company failed Wall Street by reporting EPS of $0.29, smashing the consensus of $0.30 per share. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. They issued a "neutral" rating and a $28.00 price target for the company. Also, EVP Kevin J. Ballinger sold 28,864 shares of the business's stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $26.37, for a total value of $263,700.00. The sale was disclosed in a document filed with the SEC, which is available at this link. The shares were sold at an average price of $24.55, for a total value of $1,940,554.75. Over the last three months, the shares of the company have changed -25.63% and performed -17.89% over the last six months. The disclosure for this sale can be found here. The company was able to keep return on investment at 2.60% in the last twelve months. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued.
- Ex-US Rep. Anthony Weiner pleads guilty in sexting case
- These are the real 'greatest witch hunts' in political history
- Venezuelan students lead new protests
- The 10 Countries Suffering Most The WannaCry Malware Attack
- Jubilé pour Lacazette — Lyon-Nice
- Death toll rises in southern Libya attack, defence minister suspended
- Djokovic forced to put up a fight against Almagro
- Trump says Lieberman front-runner to head Federal Bureau of Investigation
- European Investment Bank supports China's Belt and Road strategy
- Ailes was mad public believed accusers over him